quantitative
positive effect
No Evidence

Taking GlyNAC for 16 weeks significantly reduces inflammation in older adults with obesity, bringing their inflammatory markers down to levels normally seen in younger people.

Scientific Claim

GlyNAC supplementation (100 mg/kg/day each of glycine and N-acetylcysteine) for 16 weeks in older adults with BMI >27 reduced plasma interleukin-6 by 78%, tumor necrosis factor alpha by 54%, and C-reactive protein by 41%, while increasing interleukin-10 by 94%, restoring inflammatory markers to levels seen in young adults.

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

definitive

Can make definitive causal claims

Assessment Explanation

This is a randomized controlled trial with direct measurements of inflammatory markers before and after intervention. The study design supports causal claims about the specific outcome measured in this population.

Source Excerpt

Only GlyNAC supplementation resulted in improvements after 2-weeks (lowered IL-6 57%, TNFα 30%, hsCRP 25%) and after 16-weeks (lowered IL-6 78%, TNFα 54%, hsCRP 41%); and increased IL-10 after 2-weeks (by 50%) and 16-weeks (by 94%)

Evidence from Studies

Supporting Evidence (1)

Why it supports

The study measured inflammatory cytokines (IL-6, TNFα, hsCRP, IL-10) before and after GlyNAC supplementation in older adults with BMI >27. The data shows significant improvements in all measured inflammatory markers after 16 weeks of GlyNAC supplementation, with levels reaching those of young adults. Placebo group showed no improvement.